071200.Kq
The company designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic imaging and radiation therapy systems, generating revenue through product sales and service contracts.
Business. The company designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic imaging and radiation therapy systems, generating revenue through product sales and service contracts.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company designs, develops, and sells advanced medical equipment and technology, primarily focused on diagnostic imaging and radiation therapy systems, generating revenue through product sales and service contracts.
The company maintains a strong capital structure with a debt-to-equity ratio of 0.01, indicating minimal reliance on debt financing and a robust equity base. Its liquidity position is characterized by a current ratio of 5.55, suggesting ample short-term assets to cover liabilities. However, the risk assessment notes a medium liquidity risk, primarily due to a net cash position that is negative after subtracting total debt.
Profitability metrics show the company is performing well relative to industry standards. A return on equity (ROE) of 13.77% and a return on assets (ROA) of 10.61% indicate efficient use of equity and assets to generate profits. These figures are well above the typical thresholds for the healthcare equipment industry, suggesting strong operational performance and effective cost management.
The company's revenue is primarily concentrated in its core business of diagnostic imaging and radiation therapy systems, with no significant geographic diversification disclosed. This concentration may expose the company to regional market risks, particularly in its primary markets.
Looking ahead, the company is projected to maintain a stable growth trajectory. The free cash flow of 26,191,675,800 KRW and a positive operating cash flow of 13,691,104,680 KRW support ongoing operations and potential reinvestment. The capital expenditure of -433,840,480 KRW indicates a reduction in capital spending, which may signal a shift in strategic focus or a response to market conditions.
Risk factors include a medium liquidity risk and a low dilution risk. The company's low dilution potential is supported by a stable share count, with no significant changes in shares outstanding between basic and diluted figures. However, the negative net cash position after subtracting total debt suggests a need for careful liquidity management.
Recent events include the company's continued investment in R&D and product innovation, as evidenced by its strong operating income and net income figures. The company has also maintained a consistent revenue stream, supported by its leadership in the diagnostic imaging and radiation therapy markets.
- The company has a strong equity base and minimal debt, supporting a stable capital structure.
- High ROE and ROA indicate efficient use of equity and assets to generate profits.
- Revenue is concentrated in core medical equipment and technology, with limited geographic diversification.
- Free cash flow and positive operating cash flow support ongoing operations and reinvestment.
- Medium liquidity risk and a negative net cash position after debt suggest the need for careful liquidity management.
- Low dilution risk is supported by a stable share count and no significant changes in shares outstanding.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 071200.KQ Market data — financials · 2026-05-26